Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Summary

The first Part: recruiting untreated ENKL patients with extensive stage I or limited stage II disease (only referring to patients with the invasion of Waldeyer's ring and cervical lymph nodes) . Patients are randomly divided into two arms, IPGDP regimen chemotherapy followed by radiotherapy or radiotherapy followed by IPGDP regimen chemotherapy. IPGDP regimen for both arms are 3 cycles. And the chemotherapy is repeated every 3 weeks..

The second part: recruiting extensive stage II ,stage III-IV, relapsed or refractory ENKL patients. Patients receive 6 cycles of IPGDP regimen chemotherapy. And the chemotherapy is repeated every 3 weeks.

Conditions

• Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Interventions

OTHER

chemotherapy followed by radiotherapy

OTHER

radiotherapy followed by chemotherapy

DRUG

IPGDP regimen chemotherapy

Sponsors & Collaborators

• 307 Hospital of PLA

  collaborator OTHER

• Tianjin Medical University Cancer Institute and Hospital

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• The Second Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• Hebei Medical University Fourth Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Shandong Cancer Hospital and Institute

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Guangdong Provincial People's Hospital

  collaborator OTHER

• People's Hospital of Guangxi Zhuang Autonomous Region

  collaborator OTHER

• Xuzhou Medical University

  collaborator OTHER

• Shanxi Province Cancer Hospital

  collaborator OTHER

• Shanxi Dayi Hospital

  collaborator OTHER

• Zhangzhou Municipal Hospital of Fujian Province

  collaborator OTHER

• Chinese Academy of Medical Sciences

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-09-30

Primary Completion

2022-09-30

Countries

• China

Study Locations